Skip to main content
. Author manuscript; available in PMC: 2013 Mar 1.
Published in final edited form as: Mol Cancer Ther. 2012 Jan 11;11(3):639–648. doi: 10.1158/1535-7163.MCT-11-0671

Figure 2. 212Pb-TCMC-trastuzumab-induced DNA damage and repair delay in LS-174T i.p. xenografts.

Figure 2

A. Light and fluorescence microscopy images of untreated, 212Pb-TCMC-HuIgG and 212Pb-TCMC-trastuzumab at 24 h. Top, IHC staining (γH2AX); bottom, neutral comet assay (40x)

B. DNA content in the tail. DNA damage was quantified by % DNA content in the tail using comet assay at the indicated times. Results represent the average of a minimum of three replications (± SD).

C. Down-regulation of Rad51 induced by 212Pb-TCMC-trastuzumab. Immunoblot analysis for Rad51 and DNA-PKcs were performed at the 24 h time point. Rad51 was detected at 37 kDa and DNA-PKcs was detected at 450 kDa. The equivalent protein loading control was GAPDH.

D. Down-regulation of cleaved caspase-3 induced by 212Pb-TCMC-trastuzumab. Immunoblot analysis for cleaved caspase-3 was performed at the 24 h time point. Cleaved caspase-3 was detected at 17 kDa. The equivalent protein loading control was GAPDH.